In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...
A new antimalarial drug developed by Novartis is as effective as existing treatments and could help tackle rising drug ...
Clinical Trials Arena on MSN
Novartis to seek approval of anti-malaria drug on Phase III success
Based on the Phase III data, Novartis plans to seek regulatory approval from health authorities for GanLum, with the company ...
The Swiss pharmaceutical giant's plant will produce compounds needed for radioligand therapy (RLT), a form of precision ...
Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant ...
Novartis (NVS) (OTCPK:NVSEF) has announced that its next-generation malaria treatment, KLU156 (GanLum), developed with Swiss ...
Researchers are reporting two promising approaches to counteract malaria's growing drug resistance. Switzerland-based ...
Swiss drugmaker Novartis opens new manufacturing facility, part of operations expansion in the U.S. that will also invest ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...
Novartis plans to acquire Avidity Biosciences to add RNA therapeutics to its neuroscience biz to target rare genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback